Redeye believes Sdiptech's Q2 report was solid, with continued good organic sales growth in both bus...
Redeye thinks the Q2 report was slightly better than expected - being in line with consensus estimat...
Redeye’s first take on the Q2 report this morning. Despite some underlying differences, Cellavision ...
- Rec. PTP +9% vs. ABGSCe - Value changes positive, first time since Q4'22 - Earnings capacity IFPM ...
Redeye believes the major design win announced in the Q2 report sets Sivers' 5G potential in a whole...
Redeye provides a research update following the Q2 report recently published by Magle.
Redeye updates its estimates and valuation following ADDvise releasing its Q2 2024 report, which fea...
Atria's Q2 EBIT beat LSEG Data & Analytics consensus clearly.
Redeye makes minor revisions based on the Q2 report.
- We raise '24e-'26e adj. EBIT by 3-1% - Conducive conditions for organic growth - Trading at NTM EV...
- Strong momentum outside Sweden - We lower '24e-'25e EBITA by 2-1% - Share trading at 9x '24e EBITA...
- A sizeable margin improvement in both segments - EBITA estimates left largely unchanged - Trading ...
- Medicare expands lower-limb prosthetics coverage from 1 Sep - Good news for patients and Embla Med...
- EBITA SEK 245m (0% vs. ABGSCe, +2% vs. Modular Finance IR cons) - Company expects bigger vacation ...
Redeye strengthens its positive view of Vertiseit following a solid Q2 report, with 21% ARR growth a...
